IP Verse

Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R Inhibitor

Patent No. EP3515465 (titled "Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R Inhibitor") was filed by Regeneron Pharmaceuticals on Sep 21, 2017. The application was issued on Feb 7, 2024.

Patent Summary

Pharmaceutical composition containing an interleukin-4 receptor (IL-4R) inhibitor for treating severe atopic dermatitis (AD) in patients who are candidates for systemic therapy. The IL-4R inhibitor, administered as monotherapy or with topical therapy, reduces AD severity and pruritus in patients who have inadequate response or intolerance to systemic immunosuppressants, or whose AD is uncontrolled despite systemic therapy. The IL-4R inhibitor improves AD parameters like IGA, EASI, BSA, SCORAD, pruritus scales, and quality of life. It can also reduce dependence on topical corticosteroids. The IL-4R inhibitor is particularly useful for severe AD patients who are resistant, intolerant, or inadvisable for systemic immunosuppress

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BRAND MURRAY FULLERNov 7, 2024BRAND MURRAY FULLER
DORRIESNov 7, 2024DORRIES
DORRIESNov 7, 2024DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBNov 7, 2024-
BOULT WADE TENNANTNov 6, 2024BOULT WADE TENNANT
RUMINov 6, 2024TER MEER STEINMEISTER & PARTNER
SECERNANov 6, 2024SECERNA
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBNov 5, 2024ENGELHARD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3515465

REGENERON PHARMACEUTICALS
Application Number
EP17777145A
Filing Date
Sep 21, 2017
Status
Granted And Under Opposition
Jan 5, 2024
Publication Date
Feb 7, 2024
External Links
Slate, Register , Google Patents